UV Clinical A/S
Credit rating
Company information
About UV Clinical A/S
UV Clinical A/S (CVR number: 38401572) is a company from GENTOFTE. The company recorded a gross profit of 2235.5 kDKK in 2023. The operating profit was -468.8 kDKK, while net earnings were -417.2 kDKK. The profitability of the company measured by Return on Assets (ROA) was -6.8 %, which can be considered poor and Return on Equity (ROE) was -8.5 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 72.6 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. UV Clinical A/S's liquidity measured by quick ratio was 1.9 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.
Financial information
See financialsGross profit (kDKK)
EBIT (kDKK)
Profitability
Solidity
Key figures (kDKK)
See financials2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Volume | |||||
Net sales | |||||
Gross profit | - 576.66 | - 411.40 | 33.46 | 150.95 | 2 235.49 |
EBIT | -1 484.18 | -1 104.57 | -41.70 | -1 284.84 | - 468.80 |
Net earnings | -1 433.66 | -1 149.25 | 2 248.33 | - 268.89 | - 417.18 |
Shareholders equity total | - 975.21 | -2 124.46 | 123.87 | 1 677.04 | 8 163.16 |
Balance sheet total (assets) | 1 212.98 | 305.33 | 159.79 | 2 402.17 | 11 243.59 |
Net debt | - 907.93 | -15.93 | - 144.34 | - 685.93 | -4 252.63 |
Profitability | |||||
EBIT-% | |||||
ROA | -72.4 % | -47.8 % | 173.7 % | -100.3 % | -6.8 % |
ROE | -112.8 % | -151.4 % | 1047.7 % | -29.9 % | -8.5 % |
ROI | -78.3 % | -50.1 % | 186.3 % | -142.7 % | -9.4 % |
Economic value added (EVA) | -1 278.38 | - 899.47 | 65.85 | - 911.21 | - 467.83 |
Solvency | |||||
Equity ratio | -44.6 % | -87.4 % | 77.5 % | 69.8 % | 72.6 % |
Gearing | |||||
Relative net indebtedness % | |||||
Liquidity | |||||
Quick ratio | 16.0 | 1.7 | 4.3 | 2.5 | 1.9 |
Current ratio | 16.0 | 1.7 | 4.3 | 2.5 | 1.9 |
Cash and cash equivalents | 907.93 | 15.93 | 144.34 | 685.93 | 4 252.63 |
Capital use efficiency | |||||
Trade debtors turnover (days) | |||||
Net working capital % | |||||
Credit risk | |||||
Credit rating | B | B | B | B | BB |
Variable visualization
Roles
Companies in the same industry
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.